Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
IRF1
REST API REST API
Homo sapiens
IRF1 is differentially expressed in 320 experiments: 135 organism parts: lung, spleen, ... (133 more);, 208 disease states: normal, control, ... (206 more);, 109 cell types 412 cell lines 64 compound treatments and 65 other conditions.
Synonyms MAR
Orthologs Q4H3B3_CIOIN (Ciona intestinalis)   Irf1 (Mus musculus)   IRF1_CHICK (Gallus gallus)   IRF1 (Bos taurus)   irf11 (Danio rerio)   Irf1 (Rattus norvegicus)   irf1 (Xenopus laevis)   IRF1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, DNA binding, protein binding, cytokine-mediated signaling pathway, transcription, DNA-dependent, blood coagulation, transcription from RNA polymerase II promoter, I-kappaB kinase/NF-kappaB cascade, sequence-specific DNA binding, positive regulation of transcription from RNA polymerase II promoter, nucleus, regulation of gene expression, nucleoplasm, response to heat, positive regulation of transcription, DNA-dependent, response to growth hormone stimulus, cellular response to retinoic acid, female pregnancy, cellular response to mechanical stimulus, cellular response to peptide hormone stimulus, positive regulation of cell death, cellular response to tumor necrosis factor, CD8-positive, alpha-beta T cell differentiation, positive regulation of interleukin-12 biosynthetic process, cellular response to interleukin-1, sequence-specific DNA binding transcription factor activity, interferon-gamma-mediated signaling pathway, type I interferon-mediated signaling pathway, negative regulation of tyrosine phosphorylation of Stat1 protein, cellular response to dsRNA, regulatory region DNA binding
InterPro Term Interferon_reg_fac-1/2, Interferon_reg_fact_DNA-bd_dom
UniProt Accession Q6FHN8, C9J9C5, C9JD95, P10914, Q75MZ8, F8WCM1
Gene-Disease Assocation LUNG CANCER, GASTRIC CANCER, CHROMOSOME 5q DELETION SYNDROME, GASTRIC CANCER, HEREDITARY DIFFUSE; HDGC
Search EB-eye ENSG00000125347
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, E-GEOD-18105, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (42 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
SW480
3
E-GEOD-18005, E-MEXP-1014, E-MTAB-37
A549
2
E-GEOD-6013, E-GEOD-3202
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MOLT4
2
E-MTAB-37, E-MTAB-62
Raji
2
E-MTAB-37, E-GEOD-96
406 more value(s).


Cell type

studied in E-GEOD-21668, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, E-GEOD-21909, ... (49 experiments)

Factor Value U/D Experiments
CD8+ T cell
3
E-AFMX-5, E-TABM-145, E-GEOD-19069
monocyte
1
2
E-MEXP-2019, E-GEOD-8286, E-GEOD-11755
CD19+ B cell
1
E-MEXP-1600
T-ALL
1
E-GEOD-19069
endothelial cell
1
E-GEOD-96
intrathymic T progenitor cell
1
E-GEOD-1460
103 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (66 experiments)

Factor Value U/D Experiments
control
1
5
E-GEOD-16363, E-GEOD-20602, E-GEOD-3185, E-GEOD-20295, E-GEOD-20168, ... (6 experiments)
prostate cancer
2
E-MTAB-62, E-GEOD-6919
AIDS-KS, HIV+, nodular (late) stage
2
E-MTAB-62, E-MEXP-66
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
glioblastoma
2
E-GEOD-4290, E-GEOD-4412
neuroblastoma
2
E-MTAB-37, E-MTAB-62
202 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-2639, E-GEOD-1417, E-GEOD-5542, E-GEOD-5741, ... (43 experiments)

Factor Value U/D Experiments
interferon-gamma
4
E-GEOD-1432, E-GEOD-5542, E-GEOD-1925, E-GEOD-440
lipopolysaccharide
1
3
E-MEXP-1958, E-GEOD-2706, E-GEOD-4748, E-TABM-868
tumor necrosis factor
2
E-GEOD-2639, E-GEOD-2638
control
2
3
E-GEOD-3920, E-GEOD-2639, E-GEOD-440, E-GEOD-3284, E-GEOD-2638 ... (5 experiments)
control - IL-1b
1
E-GEOD-7216
1mM GDC-0941
1
1
E-GEOD-20719
58 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-MEXP-1828, E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-1140, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, ... (7 experiments)

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-3013

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-22593, E-TABM-868, E-GEOD-18005, E-TABM-601, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5809, E-GEOD-5681, E-GEOD-7011, E-GEOD-22278, E-TABM-440, ... (14 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-16194, E-TABM-276, E-GEOD-20194, E-GEOD-16716, E-GEOD-2748 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-2466, E-GEOD-1926, ... (30 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, ... (9 experiments)

Injury
studied in E-GEOD-19743

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-21750, E-GEOD-1460, E-GEOD-923 ... (5 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

Sex
studied in E-GEOD-19743, E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-12198

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.443 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM